Slide 1: Q1'25 Earnings Presentation
NASDAQ: HBIO Q1’25 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer Mark Frost, Incoming Interim CFO & Treasurer May 12, 2025 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified
Slide 3: Q1'25 Highlights
Q1’25 Highlights Stay the course, stay lean and remain focused on product commercialization and new debt facility Income Statement Components ($ in millions except percentages) Q1 2025 Q1 2024 Revenue 21.8 24.5 Gross Margin 12.2 14.8 % of Revenue 56.0% 60.3% Operating Loss (49.7)** (2.3) % of Revenu
Slide 4: Quarterly Product Revenue by Region
Fx Adjustment Quarterly Product Revenue by Region (in $M) CMT Q1'24 Q2'24 Q3'24 Q4'24 $10.97 $11.68 $11.86 $11.50 Q1'25 $9.58 Pre-Clinical $13.55 $11.42 $10.11 $13.06 $12.32 Currency ($0.13) Total $24.51 $23.10 $21.97 $24.56 $21.77 Pre-clinical CMT Americas EMEA APAC Overall: Overall: Overall: • Q1
Slide 5: Q1'25 Financial Metrics (GAAP except where noted)
Q1’25 Financial Metrics (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* per share data GROSS MARGIN $14.8 $1.6 $12.2 $0.8 EARNINGS (LOSS) PER SHARE CASH FLOW FROM OPERATIONS NET DEBT* GAAP Adjusted* Q1’25** Q1’24 Q1’25 Q1’24 * Non-GAAP measure, see Slide 10 for reconciliation to
Slide 6: New Product Introductions: Supports Long Term Growth Targets
New Product Introductions: Supports Long Term Growth Targets Growth Category New Product Introductions 2024 Achievements 2025 Goals/Achievements • Expand telemetry endpoints to include cardiac and neuro • SoHo (Shared Housing) • First shipments for temperature and • Launched commercially at March’s
Slide 7: Outlook
Outlook 7
Slide 8: Q2 2025 Outlook
Q2 2025 Outlook With uncertainty around NIH and academic research funding and the China tariff situation we now expect: ▪ Q2 Revenues ranging from $18M to $20M ▪ Q2 Gross Margin ranging from 55-57% We are focused on expanding adoption of our new products while managing costs; expect recently complet
Slide 9: Appendix
Appendix 9
Slide 10: Reconciliation to GAAP P&L
Reconciliation to GAAP P&L (1) Other operating expenses for the three months ended March 31, 2025 includes $93 thousand of restructuring-related charges and $171 thousand of employee retention tax credit fees compared to $472 thousand of employee retention tax credit fees and $494 thousand of unclai
Slide 11: Confidential & Proprietary Information
Confidential & Proprietary Information 11 11